Sind die Leitlinien das non plus ultra? Anwendung von Leitlinien bei der JIA im klinischen Alltag

Zusammenfassung

Therapieleitlinien wie sie für die Behandlung der juvenilen idiopathischen Arthritis existieren, sind erforderlich, um den Behandlern, evidenzbasierte therapeutische Strategien in lesbarer, verständlicher und einsetzbarer Form, verfügbar zu machen. In der vorliegenden Übersicht werden wichtige Aspekte der deutschen (GKJR:Gesellschaft für Kinder- und Jugendrheumatologie) und der US-amerikanischen JIA-Leitlinien diskutiert und eine Beurteilung der Qualität von Leitlinien dargestellt. Die US- und die Leitlinie der GKJR sollten aktualisiert werden, um neue Daten, z. B. im Bereich der Biologika-Therapie zu berücksichtigen. Leitlinien der Stufe S2/S3 erfordern einen sehr hohen personellen und finanziellen Aufwand, sind aber ein gutes Instrument, um Behandlern wissenschaftlich geprüfte, von Experten konsentierte und somit praktisch einsetzbare Pfade für die Behandlung von Kindern und Jugendlichen mit JIA aufzuweisen.

Abstract

Therapy guidelines like those existing for the treatment of juvenile idiopathic arthritis are necessary to provide the physician with evidence-based therapeutic options in an easily readable, understandable and applicable form. In the present review important aspects of the German and US-American guidelines for JIA are discussed and an assessment of the quality of the guidelines is presented. The American and GKJR guidelines need to be updated, to include new data, e. g., in the field of therapy with biologicals. Guidelines of the S2/S3 demand a high level investment of personal effort and costs, but are a good instrument to provide physicians with paths for scientifically proven procedures formulated under expert consensus and practical day to day approaches for the treatment of children and adolescents with JIA.

Schlüsselwörter

Juvenile idiopathische Arthritis - Leitlinien - Konsensus-bildung

Key words

juvenile idiopathic arthritis - therapy guidelines - consensus process

• Literatur

• 1 Guellac N, Niehues T. Interdisziplinäre S2-Therapieleitlinie der Juvenilen idiopathischen Arthritis. Klinische Pädiatrie 2008; 220: 392-402
• 2 Dueckers G, Guellac N, Arbogast M et al. Evidence and consensus based GKJR guidelines for the treatment of juvenile idiopathic arthritis. Clin Immunol 2012; 142: 176-193
• 3 Lehman TJ. Are withdrawal trials in paediatric rheumatic disease helpful?. Lancet 2008; 372: 348-350
• 4 Ruperto N, Lovell DJ, Cuttica R. A randomized, Plazebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2007; 56: 3096-3106
• 5 Beukelman T, Patkar NM, Saag KG et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis care Res (Hoboken) 2011; 63: 465-481
• 6 Huppertz HI, Föll D, Girschik H et al. Progress in pediatric rheumatology. Apprehend the opportunities of the future without forgetting the lessons from the past. Rheumatol Int 2011; 31: 1259-1262
• 7 Huppertz HI. Recommendations for juvenile idiopathic arthritis by the American College of Rheumatology: comment on the article by Beukelman et al. Arthritis Care Res (Hoboken) 2011; 63: 1354-1355
• 8 De Benedetti F, Brunner HI, Ruperto N et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J med 2012; 367: 2385-2395
• 9 Yokota S, Imagawa T, Mori M et al. Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan. J Rheumatol 2014; 41: 759-767
• 10 Brunner HI, Ruperto N, Zuber Z et al. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum dis 2014; oii:annrheumdis-2014-205351 DOI: 10.1136/annrheumdis-2014-205351. [Epub ahead of print]
• 11 Nigrovic PA, Mannion M, Prince FHM et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis. Arthritis Rheum 2011; 63: 545-555
• 12 Ruperto N, Brunner HI, Quartier P et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J med 2012; 367: 2396-2406
• 13 Ruperto N, Quartier P, Wulffraat N et al. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic feature. Arthritis Rheum 2012; 64: 557-567
• 14 Lovell DJ, Reiff A, Ilowite NT et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis Etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2008; 58: 1496-1504
• 15 Ruperto N, Lovell DJ, Quartier P et al. Long-term safety and efficacy of abatacept I children with juvenile idiopathic arthritis. Arthritis Rheum 2010; 62: 1792-1802
• 16 De Witt Em, Kimura Y, Beukelman T et al. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2012; 64: 1001-1010
• 17 Ringold S, Weiss PF, Colbert RA et al. Childhood arthritis and rheumatology research alliance consensus treatment plans for new-onset polyarticular juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2014; 66: 1063-1072
• 18 Munro J. Recommendations for the diagnosis and management of juvenile idiopathic arthritis, The Royal Australian College of General Practitioners, South Melbourne. 2009; 1-38 http://www.nhmrc.gov.au/_files_nhmrc/publications/attachments/cp119-juvenile-arthritis.pdf
• 19 Davies K, Cleary G, Foster H et al. BSPAR Standards of Care for children and young people with juvenile idiopathic arthritis. Rheumatology 2010; 49: 1406-1408